October 09, 2015

CariCord offers both umbilical cord blood and cord tissue banking benefits. Currently, the cells found in cord blood can be used to treat more than eighty known diseases, while the cells in cord tissue are being used in clinical trials and are not yet approved for regular human treatment. Many parents who save their baby’s cord blood also choose to save the umbilical cord tissue, because emerging research could potentially uncover viable treatment options in the not-so-distant future.

Recently in China, doctors utilized mesenchymal stem cells (which are found and collected through umbilical cord tissue banking) in a transplant for a carcinoma patient with radiation myelitis, a rare but dangerous complication that follows therapeutic irradiation to neoplasms when the spinal cord is included in the radiation field. These symptoms usually appear six to twenty-four months after the procedure and there has not been any satisfactory way to treat the symptoms of radiation myelitis. Therefore, doctors turned to mesenchymal cord tissue stem cells to treat the 37-year-old male patient.

After he was first treated, doctors followed up with the patient over periods of two days, one month, nine months, and eighteen months after transplantation using cord tissue cells. The patient was re-admitted for treatment nine months after initial discharge, but proved to be healthy at the eighteen month mark.

Though this is most likely the first time cord tissue cells have been used to treat radiation myelitis, the results have proven to be positive. This shows that stem cells collected from umbilical cord tissue could potentially be a viable future option for treating radiation myelitis in carcinoma patients.

You can read more about this procedure here.

FaceBook  Twitter